Comparison of clinical isolates and in vitro selected mutants reveals that tlyA is not a sensitive genetic marker for capreomycin resistance in Mycobacterium tuberculosis

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 6, 2011, Pages 1247-1254

  Engström, Anna ^a,b   Perskvist, Nasrin ^a   Werngren, Jim ^a   Hoffner, Sven E ^a,b   Juréen, Pontus ^a  

^a SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Amikacin; Eis; Kanamycin; MIC; Rrs; Viomycin

Indexed keywords

AMIKACIN; CAPREOMYCIN; KANAMYCIN; VIOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIUM MUTANT; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATIONAL STUDY; CROSS RESISTANCE; EIS GENE; GENE MUTATION; GENE SEQUENCE; GENETIC MARKER; GENOTYPE; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR MECHANICS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PROMOTER REGION; RRS GENE; SEQUENCE ANALYSIS; TLYA GENE;

AMIKACIN; ANTIGENS, BACTERIAL; ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; CAPREOMYCIN; DNA, BACTERIAL; DRUG RESISTANCE, BACTERIAL; GENETIC MARKERS; HUMANS; KANAMYCIN; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; POINT MUTATION; PROMOTER REGIONS, GENETIC; RNA, RIBOSOMAL, 16S; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS, DNA;

EID: 79956058701     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr109     Document Type: Article

References (26)

1. WHO. Multidrug and Extensively Drug-Resistant TB (M/XDR-TB): 2010 Global Report on Surveillance and Response. Geneva, Switzerland: WHO, 2010.
2. WHO. Stop TB Dept. Treatment of Tuberculosis: Guidelines. Geneva, Switzerland: WHO, 2010.
3. CDC. Emergence of Mycobacterium tuberculosis with Extensive Resistance to Second-Line Drugs-Worldwide, 2000-2004. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5511a2.htm (3 October 2010, date last accessed).
4. Feuerriegel S, Cox HS, ZarkuaNet al. Sequence analyses of just four genes to detect extensively drug-resistant Mycobacterium tuberculosis strains in multidrug-resistant tuberculosis patients undergoing treatment. Antimicrob Agents Chemother 2009; 53: 3353-6.
5. Hillemann D, Rusch-Gerdes S, Richter E. Feasibility of the GenoType MTBDRsl assay for fluoroquinolone, amikacin-capreomycin, and ethambutol resistance testing of Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol 2009; 47: 1767-72.
6. Balasingham SV, Davidsen T, Szpinda I et al. Molecular diagnostics in tuberculosis: basis and implications for therapy. Mol Diagn Ther 2009; 13: 137-51.
7. Brossier F, Veziris N, Aubry A et al. Detection by GenoType MTBDRsl test of complex mechanisms of resistance to second-line drugs and ethambutol in multidrug-resistant Mycobacterium tuberculosis complex isolates. J Clin Microbiol 2010; 48: 1683-9.
8. Suzuki Y, Katsukawa C, Tamaru A et al. Detection of kanamycinresistant Mycobacterium tuberculosis by identifying mutations in the 16S rRNA gene. J Clin Microbiol 1998; 36: 1220-5.
9. Taniguchi H, Chang B, Abe C et al. Molecular analysis of kanamycin and viomycin resistance in Mycobacterium smegmatis by use of the conjugation system. J Bacteriol 1997; 179: 4795-801.
10. Alangaden GJ, Kreiswirth BN, Aouad A et al. Mechanism of resistance to amikacin and kanamycin in Mycobacterium tuberculosis. Antimicrob Agents Chemother 1998; 42: 1295-7.
11. Zaunbrecher MA, Sikes RD Jr, Metchock B et al. Overexpression of the chromosomally encoded aminoglycoside acetyltransferase eis confers kanamycin resistance in Mycobacterium tuberculosis. Proc Natl Acad Sci USA 2009; 106: 20004-9.
12. Maus CE, Plikaytis BB, Shinnick TM. Mutation of tlyA confers capreomycin resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2005; 49: 571-7.
13. Johansen SK, Maus CE, Plikaytis BB et al. Capreomycin binds across the ribosomal subunit interface using tlyA-encoded 2′-O-methylations in 16S and 23S rRNAs. Mol Cell 2006; 23: 173-82.
14. Rahman A, Srivastava SS, Sneh A et al. Molecular characterization of tlyA gene product, Rv1694 of Mycobacterium tuberculosis: a non-conventional hemolysin and a ribosomal RNA methyl transferase. BMC Biochem 2010; 11: 35.
15. Stanley RE, Blaha G, Grodzicki RL et al. The structures of the anti-tuberculosis antibiotics viomycin and capreomycin bound to the 70S ribosome. Nat Struct Mol Biol 2010; 17: 289-93.
16. Maus CE, Plikaytis BB, Shinnick TM. Molecular analysis of cross-resistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2005; 49: 3192-7.
17. Jugheli L, Bzekalava N, de Rijk P et al. High level of cross-resistance between kanamycin, amikacin, and capreomycin among Mycobacterium tuberculosis isolates from Georgia and a close relation with mutations in the rrs gene. Antimicrob Agents Chemother 2009; 53: 5064-8.
18. van Ingen J, Simons S, de Zwaan R et al. Comparative study on genotypic and phenotypic second-line drug resistance testing of Mycobacterium tuberculosis complex isolates. J Clin Microbiol 2010; 48: 2749-53.
19. Werngren J, Hoffner SE. Drug-susceptible Mycobacterium tuberculosis Beijing genotype does not develop mutation-conferred resistance to rifampin at an elevated rate. J Clin Microbiol 2003; 41: 1520-4.
20. Jureen P, Engstrand L, Eriksson S et al. Rapid detection of rifampin resistance in Mycobacterium tuberculosis by pyrosequencing technology. J Clin Microbiol 2006; 44: 1925-9.
21. Kruuner A, Jureen P, Levina K et al. Discordant resistance to kanamycin and amikacin in drug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 2003; 47: 2971-3.
22. Hall T. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucl Acids Symp Ser 1999; 41: 95-8.
23. Camus JC, Pryor MJ, Medigue C et al. Re-annotation of the genome sequence of Mycobacterium tuberculosis H37Rv. Microbiology 2002; 148: 2967-73.
24. Schon T, Jureen P, Giske CG et al. Evaluation of wild-type MIC distributions as a tool for determination of clinical breakpoints for Mycobacterium tuberculosis. J Antimicrob Chemother 2009; 64: 786-93.
25. Jureen P, Angeby K, Sturegard E et al. Wild-type MIC distributions for aminoglycoside and cyclic polypeptide antibiotics used for treatment of Mycobacterium tuberculosis infections. J Clin Microbiol 2010; 48: 1853-8.
26. WHO. Policy Guidance on Drug-Susceptibility Testing (DST) of Second-Line Antituberculosis Drugs. Geneva, Switzerland: WHO, 2008.